FibroScan-Reproducibility and Repeatability Study

Launched by ECHOSENS · Mar 13, 2025

Keywords

ClinConnect Summary

The FibroScan-Reproducibility and Repeatability Study is looking into how reliable and consistent a non-invasive device called FibroScan is for measuring liver stiffness and fat content in patients with liver diseases, such as Non-Alcoholic Fatty Liver Disease and Alcohol-Related Liver Disease. This study is important because detecting liver scarring early can help prevent serious complications like liver cancer. The researchers want to see if FibroScan gives similar results when used by different operators and on different days, which can improve trust in its use for monitoring liver health.

To participate in the study, adults aged 18 and older who have specific liver diseases like Metabolic Dysfunction Associated Steatotic Liver Disease or Alcohol-related Liver Disease can apply. Participants will visit the clinic twice within three days, where they will undergo multiple FibroScan scans, provide blood samples to check liver health, and fill out a brief questionnaire. Each visit will take about 25 to 45 minutes. This research, funded by the manufacturer of FibroScan, aims to enhance the understanding of how effectively the device works across various settings, ultimately benefiting those with chronic liver conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients (age ≥ 18 y.o) with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD), Metabolic and Alcohol-related Liver Disease (MetALD), and Alcohol-related Liver Disease (ALD).
• • Adult patients able to give written informed consent.
• Exclusion Criteria:
• • Vulnerable patients
• • Patients with other chronic liver disease including but not limited to hepatitis B, hepatitis C, autoimmune hepatitis, cholestatic diseases
• • Patients with ascites
• • Patients with elevated conjugated bilirubin (\>1.5 ULN)
• • Patients with heart failure